We have located links that may give you full text access.
Comment
Journal Article
Randomized Controlled Trial
Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia.
Expert Opinion on Investigational Drugs 2009 June
BACKGROUND: In asthma, anti-inflammatory therapy can usually reduce airway eosinophilic inflammation; but in certain subgroups this persists despite maximal therapy, and disease control is suboptimal. Mepolizumab is an anti IL-5. antibody that might reduce airway inflammation in such subgroups.
METHODS AND RESULTS: Evaluation of the efficacy and safety data on mepolizumab in two studies performed in patients with refractory and corticosteroid-dependent asthma with persistent sputum eosinophilia. Mepolizumab given intravenously once a month was able to reduce sputum/blood eosinophilia and asthma exacerbations and to improve quality of life.
CONCLUSIONS: Mepolizumab may be a promising anti-inflammatory therapy in asthma subgroups with heavy eosinophilic load in which conventional anti-inflammatory therapy is only partially effective.
METHODS AND RESULTS: Evaluation of the efficacy and safety data on mepolizumab in two studies performed in patients with refractory and corticosteroid-dependent asthma with persistent sputum eosinophilia. Mepolizumab given intravenously once a month was able to reduce sputum/blood eosinophilia and asthma exacerbations and to improve quality of life.
CONCLUSIONS: Mepolizumab may be a promising anti-inflammatory therapy in asthma subgroups with heavy eosinophilic load in which conventional anti-inflammatory therapy is only partially effective.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app